NICE issues guidance for use of pemetrexed disodium for the treatment of malignant pleural mesothelioma (TA 135)

Abstract The National Institute for Health and Clinical Excellence (NICE) has issued a Technology Appraisal for the use of pemetrexed for the treatment of malignant pleural mesothelioma, and makes the following recommendations (taken directly from source):

• Pemetrexed is recommended as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organisation (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate

• Patients currently receiving pemetrexed who do not fall into the patient population defined above should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Source - NICE

To contact one of our specialist lawyers please call 0800 61 66 81, or use the contact details at the top left of this page.